Auxxo
European seed investor participating in BioOrbit's £9.8m round.
Last refreshed: 1 May 2026 · Appears in 1 active topic
How does Auxxo support female-founded deep-tech startups in Europe?
Timeline for Auxxo
Mentioned in: BioOrbit raises £9.8m for orbital pharma
UK Startups and Innovation- What does Auxxo invest in?
- Auxxo is a Berlin-based seed VC with a mandate to back female-founded companies at pre-seed and seed. It focuses on B2B software, health and deep tech, and typically co-invests alongside larger European funds.Source: Auxxo public record
- Who is behind Auxxo venture capital?
- Auxxo was founded in 2021 by Constanze Buchheim and Catharina van Delden, two German entrepreneurs and executives with backgrounds in HR-tech and innovation.Source: Auxxo public record
- Why did Auxxo participate in BioOrbit's seed round?
- Auxxo joined BioOrbit's £9.8m seed in April 2026 as part of a multi-investor syndicate including LocalGlobe and Breega. BioOrbit's female co-founders align with Auxxo's mandate to back female-founded deep-tech companies.
Background
Auxxo is a Berlin-based seed-stage venture capital firm founded in 2021 with an explicit mandate to back female-founded companies at pre-seed and seed. The fund was established by Constanze Buchheim and Catharina van Delden, two German entrepreneurs with backgrounds in HR-tech and innovation consulting, with the thesis that female-founded startups are systematically underserved by mainstream European VC. Auxxo typically writes initial cheques of €250,000 to €1m and focuses on B2B software, health, and deep tech.
The fund is a participant investor rather than a lead, often co-investing alongside larger European seed funds. Its presence in cross-border syndicates signals both the EU-facing Nature of the UK deep-tech ecosystem and a broadening of the capital sources that back British science-led companies. Auxxo participated in BioOrbit's £9.8m in-space drug manufacturing seed round in April 2026, alongside LocalGlobe, Breega, Seedcamp, Type One and 7percent.
Auxxo's involvement in BioOrbit is representative of a pattern in the 2026 UK funding window: international specialist funds entering British rounds as part of multi-investor syndicates rather than leading standalone national rounds. For BioOrbit's founding team, which includes female co-founders, Auxxo's participation is consistent with the fund's stated thesis.